Eradication of Bacteria from Infected Eyes by a Three Day BID Treatment with Moxifloxacin Ophthalmic Solution 0.5%

Abstract

Abstract: : Purpose: To determine the effectiveness of a 3 day BID regimen with Moxifloxacin Ophthalmic Solution 0.5% in eradicating pathogens of bacterial conjunctivitis. Methods: 140 patients with confirmed bacterial conjunctivitis were enrolled in this study. Pre-therapy cultures determined the etiological agent of the bacterial conjunctivitis. Patients were treated topically BID for 3 days with either Moxifloxacin Ophthalmic Solution 0.5% or placebo. Cultures were taken again at the test-of-cure visit [Day 5] after three days of BID therapy and two days off therapy. Microbiological success was judged as complete elimination [eradication] of the bacterial pathogen on Day 5. Results: 116 patients of the 140 (83%) enrolled were culture positive for bacteria at the pre-therapy visit. For the 53 patients treated with Moxifloxacin Ophthalmic Solution 0.5% BID for 3 days, 43 (81%) were classified as microbiological successes at the test-of-cure visit, i.e., all pre-therapy pathogens were eradicated. This rate was superior to that for the placebo treatment group. Moxifloxacin Ophthalmic Solution 0.5% eradicated 100% of Staphylococcus epidermidis, and S. aureus isolates. Even the single strains of Pseudomonas aeruginosa and Serratia marcescens were also eradicated. Antibiotic susceptibilities of the isolates that were eradicated included some that were resistant to other fluoroquinolones, methicillin, aminoglycosides and/or erythromycin. Conclusions: The microbiological eradication rate of 81% for Moxifloxacin Ophthalmic Solution 0.5% treated BID for 3 days supports the effectiveness of this ophthalmic antibiotic preparation in eliminating the agents of bacterial conjunctivitis.

Keywords: antibiotics/antifungals/antiparasitics • conjunctivitis • clinical (human) or epidemiologic studies: tre